Mesaconate

1 paper4 findings

PubChem 638129 ChEBI 16600

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funder: National Natural Science Foundation of China

Animals1

Outcomes

4

Ferroptosis

downin mouse cells1

1 study

Mesaconate inhibits ferroptosis in mouse cells.
“mesaconate alleviates macrophage ferroptosis via GPR35, thereby contributing to its anti-inflammatory effects”
Cellsin bone marrow-derived macrophages
Mesaconate Alleviates Myocardial Ischemia/Reperfusion Injury and Cardiovascular Aging by Targeting GPR35 to Arrest Macrophage Inflammation
Inflammation25 Feb 2026

More on Ferroptosis

Cardiac hypertrophy

downin mice1

1 study

Mesaconate decreases cardiac hypertrophy in mice.
“In aged mice, mesaconate ameliorated cardiac hypertrophy and vascular dysfunction”
Animalsin aged mice
Mesaconate Alleviates Myocardial Ischemia/Reperfusion Injury and Cardiovascular Aging by Targeting GPR35 to Arrest Macrophage Inflammation
Inflammation25 Feb 2026

Systolic function

upin mice1

1 study

Mesaconate improves systolic function in mice.
“improved systolic function, and reduced infarct size”
Animalsin myocardial ischemia/reperfusion model
Mesaconate Alleviates Myocardial Ischemia/Reperfusion Injury and Cardiovascular Aging by Targeting GPR35 to Arrest Macrophage Inflammation
Inflammation25 Feb 2026

Infarct size

downin mice1

1 study

Mesaconate decreases infarct size in mice.
“In a myocardial ischemia/reperfusion model, mesaconate significantly attenuated cardiac injury, improved systolic function, and reduced infarct size”
Animalsin myocardial ischemia/reperfusion model
Mesaconate Alleviates Myocardial Ischemia/Reperfusion Injury and Cardiovascular Aging by Targeting GPR35 to Arrest Macrophage Inflammation
Inflammation25 Feb 2026

Latest

1 in 12 months

Inflammation25 Feb

Mesaconate Alleviates Myocardial Ischemia/Reperfusion Injury and Cardiovascular Aging by Targeting GPR35 to Arrest Macrophage Inflammation

Experiments in miceInterventions

NPJ Biofilms and Microbiomes20 Aug

Mesaconic acid as a key metabolite with anti-inflammatory and anti-aging properties produced by Lactobacillus plantarum 124 from centenarian gut microbiota

Study in peopleInterventions